Sub‐ and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study
Authors:
Open Access
- 8 October 2024
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (2) , 464-478
Abstract
Aims: Interindividual variations in efavirenz (EFV) plasma concentrations are extensive, but paediatric data on its consequences for viral control are scarce. The aim of this study was to explore the role of genetic variation in achieving therapeutic efavirenz plasma concentrations in a cohort of Ugandan children and the linkage between genetic CYP2B6 variants, EFV plasma variability, viral resistance and viral outcome.Methods: Ninety‐nine treatment‐naïve children, aged 3–12 years and living with HIV, were followed for 24 weeks after ART initiation assessing mid‐dose efavirenz plasma concentrations, HIV RNA, HIV drug resistance and adherence. Polymorphisms in genes coding for drug‐metabolizing enzymes were genotyped. Efavirenz concentrations were determined by liquid chromatography coupled with high‐resolution tandem mass spectrometry. Metabolizer phenotype was predicted from composite genotypes of CYP2B6 (c.516G>T and c.983 T>C). A mixed effects restricted maximum likelihood regression model was used to identify important factors for efavirenz exposure.Results: Efavirenz plasma concentrations were below the therapeutic interval (1000–4000 mg/mL) in 12–17% and above in 21–24% of measurements. Eight children had persisting subtherapeutic concentrations, five of which failed virologically and three acquired at least one new resistant mutation. Multivariate modelling explained 70% of interindividual variation in plasma concentration, with treatment duration, adherence, CYP2B6c.136A>G, and metabolizer phenotype as independent predictors of EFV concentration. In univariate analysis, metabolizer phenotype explained 50% of interindividual variation.Conclusions: Metabolizer phenotype explained 50% of interindividual variation in efavirenz plasma concentration. Autoinduction was not confirmed and >33% of the concentrations were outside the therapeutic interval. Subtherapeutic concentrations worsened virological resistance and outcomes. Genotype‐based dosing may help avert both sub‐ and supratherapeutic efavirenz plasma concentrations in Ugandan children.Keywords
This publication has 69 references indexed in Scilit:
- Physiologically Based Pharmacokinetic Modeling to Determine the Impact of CYP2B6 Genotype on Efavirenz Exposure in Children, Mothers and Breastfeeding InfantsClinical Pharmacology & Therapeutics, 2023
- Genetic and non‐genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus‐1‐infected children in EthiopiaCPT: Pharmacometrics & Systems Pharmacology, 2023
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral TherapyClinical Pharmacology & Therapeutics, 2019
- Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without TuberculosisClinical Pharmacology & Therapeutics, 2011
- Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV PatientsClinical Pharmacology & Therapeutics, 2010
- Effect ofCYP2B6,ABCB1, andCYP3A5Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group StudyThe Journal of Infectious Diseases, 2010
- Human hepatic CYP2B6 developmental expression: The impact of age and genotypeBiochemical Pharmacology, 2009
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Pharmacokinetics and Pharmacodynamics of Efavirenz and Nelfinavir in HIV-infected Children Participating in an Area-under-the-curve Controlled TrialClinical Pharmacology & Therapeutics, 2007
- Influence of 516G>T Polymorphisms at the Gene Encoding the CYP450-2B6 Isoenzyme on Efavirenz Plasma Concentrations in HIV-Infected SubjectsClinical Infectious Diseases, 2005